Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer

Prostate

Volumn 70, Issue 10, 2010, Pages 1134-1145

  Thompson, Vanessa C ^a   Hurtado Coll, Antonio ^a   Turbin, Dmitry ^b   Fazli, Ladan ^a   Lehman, Melanie L ^a   Gleave, Martin E ^a   Nelson, Colleen C ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

catenin; Androgen ablation; Autocrine; Castration resistant prostate cancer; Paracrine; RXFP1

Indexed keywords

ANDROGEN RECEPTOR; CADHERIN; PROTOCADHERIN Y; RELAXIN; UNCLASSIFIED DRUG; VASCULOTROPIN; WNT PROTEIN; WNT11 PROTEIN; BETA CATENIN; CATNB PROTEIN, MOUSE; G PROTEIN COUPLED RECEPTOR; LGR7 PROTEIN, MOUSE; RECEPTOR; RNA; RXFP1 PROTEIN, HUMAN; WNT1 PROTEIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CASTRATION; CELL STRAIN LNCAP; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NORTHERN BLOTTING; NUDE MOUSE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CHEMISTRY; DNA MICROARRAY; GENETICS; METABOLISM; NEOPLASM; NONPARAMETRIC TEST; PROSTATE TUMOR; TUMOR CELL LINE; UPREGULATION; XENOGRAFT;

ANIMALS; BETA CATENIN; BLOTTING, NORTHERN; CADHERINS; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PEPTIDE; RELAXIN; RNA; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION; WNT1 PROTEIN;

EID: 77953380098     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21148     Document Type: Article

References (45)

1. Yki-Jarvinen H, Wahlstrom T, Seppala M. Immunohistochemical demonstration of relaxin in the genital tract of men. J Reprod Fertil 1983;69(2):693-695. (Pubitemid 13021977)
2. Sokol RZ, Wang XS, Lechago J, Johnston PD, Swerdloff RS. Immunohistochemical localization of relaxin in human prostate. J Histochem Cytochem 1989;37(8):1253-1255. (Pubitemid 19186026)
3. Gunnersen JM, Crawford RJ, Tregear GW. Expression of the relaxin gene in rat tissues. Mol Cell Endocrinol 1995;110(1-2): 55-64.
4. De Cooman S, Gilliaux P, Thomas K. Immunoreactive relaxin-like substance in human split ejaculates. Fertil Steril 1983; 39(1):111-113. (Pubitemid 13110716)
5. Schieferstein G, Voelter W, Seeger H, Lippert TH. Immunoreactive relaxin in seminal plasma of man. Int J Fertil 1989;34(3): 215-218. (Pubitemid 19255498)
6. Bani D. Relaxin: A pleiotropic hormone. Gen Pharmacol 1997; 28(1):13-22.
7. Silvertown JD, Ng J, Sato T, Summerlee AJ, Medin JA. H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis. Int J Cancer 2006;118(1):62-73.
8. Vinall RL, Tepper CG, Shi XB, Xue LA, Gandour-Edwards R, de Vere White RW. The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7. Oncogene 2006;25(14):2082-2093.
9. Feng S, Agoulnik IU, Bogatcheva NV, Kamat AA, Kwabi-Addo B, Li R, Ayala G, Ittmann MM, Agoulnik AI. Relaxin promotes prostate cancer progression. Clin Cancer Res 2007;13(6):1695-1702.
10. Silvertown JD, Symes JC, Neschadim A, Nonaka T, Kao JCH, Summerlee AJS, Medin JA. Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth. FASEB J 2007;21(3):754-765.
11. Thompson VC, Morris TG, Cochrane DR, Cavanagh J, Wafa LA, Hamilton T, Wang S, Fazli L, Gleave ME, Nelson CC. Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens. Prostate 2006;66(16):1698-1709.
12. Chen MW, Vacherot F, De La Taille A, Gil-Diez-De-Medina S, Shen R, Friedman RA, Burchardt M, Chopin DK, Buttyan R. The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells. Oncogene 2002;21(51):7861-7871.
13. de la Taille A, Rubin MA, Chen M-W, Vacherot F, de Medina SGD, Burchardt M, Buttyan R, Chopin D. {beta}-Catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res 2003;9(5):1801-1807. (Pubitemid 36554607)
14. Yang X, Chen MW, Terry S, Vacherot F, Chopin DK, Bemis DL, Kitajewski J, Benson MC, Guo Y, Buttyan R. A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells. Cancer Res 2005;65(12):5263-5271.
15. Terry S, Queires L, Gil-Diez-de-Medina S, Chen MW, de la Taille A, Allory Y, Tran PL, Abbou CC, Buttyan R, Vacherot F. Protocadherin-PC promotes androgen-independent prostate cancer cell growth. Prostate 2006;66(10):1100- 1113.
16. Ulrich F, Krieg M, Schotz EM, Link V, Castanon I, Schnabel V, Taubenberger A, Mueller D, Puech PH, Heisenberg CP. Wnt11 functions in gastrulation by controlling cell cohesion through Rab5c and E-cadherin. Dev Cell 2005;9(4):555-564.
17. Ulrich F, Concha ML, Heid PJ, Voss E, Witzel S, Roehl H, Tada M, Wilson SW, Adams RJ, Soll DR, Heisenberg CP. Slb/Wnt11 controls hypoblast cell migration and morphogenesis at the onset of zebrafish gastrulation. Development 2003;130(22):5375-5384.
18. Ouko L, Ziegler TR, Gu LH, Eisenberg LM, Yang VW. Wnt11 signaling promotes proliferation, transformation, and migration of IEC6 intestinal epithelial cells. J Biol Chem 2004;279(25): 26707-26715.
19. Zhu H, Mazor M, Kawano Y, Walker MM, Leung HY, Armstrong K, Waxman J, Kypta RM. Analysis of Wnt gene expression in prostate cancer: Mutual inhibition by WNT11 and the androgen receptor. Cancer Res 2004;64(21):7918-7926.
20. Rennie PS, Bruchovsky N, Leco KJ, Sheppard PC, McQueen SA, Cheng H, Snoek R, Hamel A, Bock ME, MacDonald BS. Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol 1993;7(1):23-36.
21. Snoek R, Rennie PS, Kasper S, Matusik RJ, Bruchovsky N. Induction of cell-free, in vitro transcription by recombinant androgen receptor peptides. J Steroid Biochem Mol Biol 1996; 59(3-4):243-250. (Pubitemid 27037930)
22. Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 1992;52(6):1598-1605.
23. Kojima S, Mulholland DJ, Ettinger S, Fazli L, Nelson CC, Gleave ME. Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models. Prostate 2006; 66(9):971-986.
24. Yamanaka K, Rocchi P, Miyake H, Fazli L, So A, Zangemeister-Wittke U, Gleave ME. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. BJU Int 2006;97(6):1300-1308.
25. Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, Miyake H, Gleave ME. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 2003;63(13):3575-3584. (Pubitemid 36793038)
26. Zhou W, Lin L, Majumdar A, Li X, Zhang X, Liu W, Etheridge L, Shi Y, Martin J, Van de Ven W, Kaartinen V, Wynshaw-Boris A, McMahon AP, Rosenfeld MG, Evans SM. Modulation of morphogenesis by noncanonical Wnt signaling requires ATF/ CREB family-mediated transcriptional activation of TGFbeta2. Nat Genet 2007;39(10):1225-1234.
27. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68(15):6407-6415.
28. Thompson VC, Lehman M, Lubik AA, Neira M, Altamirano M, Hendy SC, Nelson CC. Androgens upregulate IRS-2 which potentiates IGF-1 and androgen signaling. In Preparation.
29. Binder C, Hagemann T, Husen B, Schulz M, Einspanier A. Relaxin enhances in-vitro invasiveness of breast cancer cell lines by up-regulation of matrix metalloproteases. Mol Hum Reprod 2002;8(9):789-796. (Pubitemid 35012465)
30. Radestock Y, Hoang-Vu C, Hombach-Klonisch S. Relaxin down-regulates the calcium binding protein S100A4 in MDA-MB-231 human breast cancer cells. Ann NY Acad Sci 2005; 1041:462-469.
31. Hombach-Klonisch S, Bialek J, Trojanowicz B,Weber E, Holzhausen HJ, Silvertown JD, Summerlee AJ, Dralle H, Hoang-Vu C, Klonisch T. Relaxin enhances the oncogenic potential of human thyroid carcinoma cells. Am J Pathol 2006; 169(2):617-632.
32. Kamat AA, Feng S, Agoulnik IU, Kheradmand F, Bogatcheva NV, Coffey D, Sood AK, Agoulnik AI. The role of relaxin in endometrial cancer. Cancer Biol Ther 2006;5(1):71-77.
33. Christiansen JH, Monkley SJ, Wainwright BJ. Murine WNT11 is a secreted glycoprotein that morphologically transforms mammary epithelial cells. Oncogene 1996;12(12):2705-2711.
34. Silvertown JD, Geddes BJ, Summerlee AJ. Adenovirus-mediated expression of human prorelaxin promotes the invasive potential of canine mammary cancer cells. Endocrinology 2003;144(8): 3683-3691.
35. Terry S, Yang X, Chen MW, Vacherot F, Buttyan R. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. J Cell Biochem 2006; 99(2):402-410. (Pubitemid 44435558)
36. Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB. Detection and analysis of beta-catenin mutations in prostate cancer. Prostate 2000;45(4):323-334.
37. Fox S, Dharmarajan A. WNT signaling in malignant mesothelioma. Front Biosci 2006;11:2106-2112.
38. Daniel VC, Peacock CD, Watkins DN. Developmental signalling pathways in lung cancer. Respirology 2006;11(3):234-240.
39. Pearse RN. Wnt antagonism in multiple myeloma: A potential cause of uncoupled bone remodeling. Clin Cancer Res 2006; 12(20 Pt 2):6274s-6278s.
40. Radtke F, Clevers H. Self-renewal and cancer of the gut: Two sides of a coin. Science 2005;307(5717):1904-1909.
41. Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC. The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem 2002;277(20):17933-17943.
42. Song LN, Herrell R, Byers S, Shah S, Wilson EM, Gelmann EP. Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol 2003;23(5):1674-1687.
43. Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: A means for inhibition of the Tcf signaling axis. Oncogene 2003;22(36):5602-5613.
44. Chesire DR, Isaacs WB. Ligand-dependent inhibition of betacatenin/ TCF signaling by androgen receptor. Oncogene 2002; 21(55):8453-8469.
45. Liu S, Vinall RL, Tepper C, Shi XB, Xue LR, Ma AH, Wang LY, Fitzgerald LD, Wu Z, Gandour-Edwards R, deVere White RW, Kung HJ. Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway. Oncogene 2008;27(4):499-505.